J Gregory Cairncross1, Meihua Wang, Robert B Jenkins, Edward G Shaw, Caterina Giannini, David G Brachman, Jan C Buckner, Karen L Fink, Luis Souhami, Normand J Laperriere, Jason T Huse, Minesh P Mehta, Walter J Curran. 1. J. Gregory Cairncross, University of Calgary, Calgary, Alberta; Luis Souhami, McGill University, Montreal, Quebec; Normand J. Laperriere, University of Toronto, Toronto, Ontario, Canada; Meihua Wang, American College of Radiology, Philadelphia, PA; Robert B. Jenkins, Caterina Giannini, and Jan C. Buckner, Mayo Clinic, Rochester, MN; Edward G. Shaw, Wake Forest School of Medicine, Winston-Salem, NC; David G. Brachman, Arizona Oncology Services Foundation/Barrow Neurological Institute, Phoenix, AZ; Karen L. Fink, Baylor University, Dallas, TX; Jason T. Huse, Memorial Sloan-Kettering Cancer Center, New York, NY; Minesh P. Mehta, Northwestern University, Chicago, IL; and Walter J. Curran Jr, Emory University, Atlanta, GA.
Abstract
PURPOSE:Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT. PATIENTS AND METHODS: Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT. RESULTS:IDH status was evaluable in 210 of 291 patients; 156 (74%) had mutations. rs55705857 was evaluable in 245 patients; 76 (31%) carried the G risk allele. Both were associated with longer progression-free survival after CRT, and mutant IDH was associated with longer overall survival (9.4 v 5.7 years; hazard ratio [HR], 0.59; 95% CI, 0.40 to 0.86; P = .006). For those with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95% CI, 0.63 to 2.04; P = .67) or 10-year survival rate (CRT, 6% v RT, 4%). Patients with codeleted mutated tumors (14.7 v 6.8 years; HR, 0.49; 95% CI, 0.28 to 0.85; P = .01) and noncodeleted mutated tumors (5.5 v 3.3 years; HR, 0.56; 95% CI, 0.32 to 0.99; P < .05) lived longer after CRT than RT. CONCLUSION: IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT. Although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.
RCT Entities:
PURPOSE:Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after chemoradiotherapy (CRT) than radiation therapy (RT) alone. However, some patients with noncodeleted tumors also benefited from CRT; survival curves separated after the median had been reached, and significantly more patients lived ≥ 10 years after CRT than RT. Thus, 1p/19q status may not identify all responders to CRT. PATIENTS AND METHODS: Using trial data, we inquired whether an IDH mutation or germ-line polymorphism associated with IDH-mutant gliomas identified the patients in RTOG 9402 who benefited from CRT. RESULTS:IDH status was evaluable in 210 of 291 patients; 156 (74%) had mutations. rs55705857 was evaluable in 245 patients; 76 (31%) carried the G risk allele. Both were associated with longer progression-free survival after CRT, and mutant IDH was associated with longer overall survival (9.4 v 5.7 years; hazard ratio [HR], 0.59; 95% CI, 0.40 to 0.86; P = .006). For those with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95% CI, 0.63 to 2.04; P = .67) or 10-year survival rate (CRT, 6% v RT, 4%). Patients with codeleted mutated tumors (14.7 v 6.8 years; HR, 0.49; 95% CI, 0.28 to 0.85; P = .01) and noncodeleted mutated tumors (5.5 v 3.3 years; HR, 0.56; 95% CI, 0.32 to 0.99; P < .05) lived longer after CRT than RT. CONCLUSION:IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT. Although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.
Authors: Tod Duncan; Sarah C Trewick; Pertti Koivisto; Paul A Bates; Tomas Lindahl; Barbara Sedgwick Journal: Proc Natl Acad Sci U S A Date: 2002-12-16 Impact factor: 11.205
Authors: Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape Journal: Cancer Cell Date: 2010-04-15 Impact factor: 31.743
Authors: O L Chinot; S Honore; H Dufour; M Barrie; D Figarella-Branger; X Muracciole; D Braguer; P M Martin; F Grisoli Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: M J van den Bent; M J B Taphoorn; A A Brandes; J Menten; R Stupp; M Frenay; O Chinot; J M Kros; C C D van der Rijt; Ch J Vecht; A Allgeier; T Gorlia Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Martin J van den Bent; Hendrikus J Dubbink; Yannick Marie; Alba A Brandes; Martin J B Taphoorn; Pieter Wesseling; Marc Frenay; Cees C Tijssen; Denis Lacombe; Ahmed Idbaih; Ronald van Marion; Johan M Kros; Winand N M Dinjens; Thierry Gorlia; Marc Sanson Journal: Clin Cancer Res Date: 2010-02-16 Impact factor: 13.801
Authors: Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner Journal: N Engl J Med Date: 2009-02-19 Impact factor: 176.079
Authors: François Ducray; Ahmed Idbaih; Aurélien de Reyniès; Ivan Bièche; Joëlle Thillet; Karima Mokhtari; Séverine Lair; Yannick Marie; Sophie Paris; Michel Vidaud; Khê Hoang-Xuan; Olivier Delattre; Jean-Yves Delattre; Marc Sanson Journal: Mol Cancer Date: 2008-05-20 Impact factor: 27.401
Authors: Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran Journal: N Engl J Med Date: 2016-04-07 Impact factor: 91.245